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Clinical Exacerbations as a Surrogate End Point in Heart Failure Research
Abstract
Background
We examined the utility of an index of clinical exacerbations of heart failure (HF) as a surrogate measure of
outcome for use in modestly sized clinical trials and observational studies.
Methods
Electronic records of 189 outpatients with HF in a US Veterans Affairs Medical Center were examined over a
2- to 3-year period. Data collected included patient characteristics, clinical exacerbations of HF,
hospitalizations, and deaths. Subsets of patient were also assessed for HF-related level of functioning.
Results
Episodes of clinical exacerbation could be detected reliably (kappa = .83). An index of episodes (number of
episodes divided by the time in years) was associated with lower quality of life, higher functional class,
increased rate of HF hospitalization, poorer exercise tolerance, and up to 30% increased risk of mortality
across 2 years.
Conclusions
The index of HF exacerbations is potentially a useful surrogate end point for use in clinical HF research.
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ABSTRACT 
 
Purpose: An index of a patients’ rate of clinical exacerbations of heart failure (HF) was examined 
as a surrogate endpoint in clinical outcome.  
Method:  One hundred ninety-one patients with HF were followed subsequent to their entry into a 
clinical screening database when being considered for study of treatment adherence. The patients’ 
electronic records were examined retrospectively over a 2 – 3 year period regarding their demographic 
and clinical characteristics, clinical exacerbations of heart failure, hospitalizations, and deaths. Some 
these patients were also assessed using measures of depression (N = 40), HF-specific quality of life (HF-
QOL), and exercise tolerance (6-minute walk test). 
Results: Two trained research assistants were able to reliably code patients’ clinical visits with 
regard to the existence of clinical exacerbations of HF (kappa = .83). An index of the chart-extracted 
exacerbations (CEEs) of HF was associated with lower HF-QOL, relatively higher New York Heart 
Association (NYHA) Class, and poorer exercise tolerance. The index of CEEs was also associated with 
the risk of mortality; 54% of the patients with greater than 2 CEEs per year died within a 2-year follow-up 
period, whereas only 27% of patients with 2 or fewer CEEs per died within the same follow-up period. 
Conclusions: This index of CEEs is potentially a useful surrogate endpoint for use in clinical HF 
research. Future research should examine the patterns of clinical exacerbations over time and the utility of 
this index in predicting mortality risk on a prospective basis. 
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Heart failure (HF) is a highly prevalent clinical syndrome that represents a great burden to the 
patient and family members, and is associated with a 50% mortality risk over 5 years.[1] Consistent with 
the high mortality risk of HF, the reduction of this risk has been the gold standard clinical endpoint used 
in most investigations of interventional medications [2]. However, as treatments have lengthened survival 
of patients with CHF, increasingly larger samples are required to show improved survival risk for newer 
treatments [2]. Thus, there has been recent increase in the consideration of surrogate end points (e.g., 
exercise capacity, left ventricle ejection fraction), potentially as a way to lower the demands in a clinical 
trial for sample size and reduce the time needed to evaluate the potential usefulness of a medication or 
treatment strategy. Disease-related quality of life (QOL) has also been considered an important “true” end 
point, in that specific interventions may prolong life but not contribute significantly to improved 
functioning or well-being from the patient’s point of view. Most investigators would consider reduced 
symptoms and improved functioning important to the overall management of HF, although some 
treatments that improve QOL also appear to adversely affect survival. [3-5] Thus, QOL is considered an 
important and separate dimension of health status[6], and potentially an important component of a 
surrogate end point in studies of CHF treatment. 
The purpose of the current study is to propose an index of chart-extracted clinical exacerbations 
or decompensations of HF as a useful surrogate end point, and present data support the reliability and 
validity of this end point. Exacerbations of heart failure as extracted from chart information over time 
may have a number of practical applications, including epidemiological studies not allowing extensive 
examinations of disease related quality of life, studies of health care systems of the process and quality of 
care, as well as a refinement of hospitalization as a near term surrogate end point of studies that also use 
the gold standard of mortality as an end point. Because a chart-extracted clinical exacerbation of HF also 
represents a significant worsening of symptoms, it is likely that HF–related QOL is reflected in this 
surrogate end point. Patients who spend a significant amount of time in a clinically decompensated state 
will likely have worse QOL. 
Anand and colleagues [2] described several types of surrogate end points, including a strong 
surrogate, which refer to antecedent outcomes that have been definitively established as directly related 
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to a gold standard outcome (eg., strong surrogate: lowered hypertension—gold standard: cardiovascular 
events such as stroke). Chart-extracted clinical exacerbations are closer to two other types of surrogate 
end points, namely, developmental and supportive surrogates. A developmental surrogate refers to an 
outcome that has preliminary evidence indicating it is closely related to an important end point, and a 
supportive surrogate refers to an outcome that appears to be closely related and predictive of a beneficial 
outcome. Patients who are volume-overloaded with accompanying symptoms of increased weight, edema, 
shortness of breath, and reduced exercise tolerance are at greater risk of ventricular arrhythmias and 
sudden death due to cardiac arrest (ref). Patients who spend relatively greater time in this clinically 
decompensated state are at greater risk for permanent worsening of their clinical status (ref), and thus, 
increasing the risk of mortality in the near term. 
Validation of a surrogate endpoint is never fully complete [2] although important criteria that 
support a surrogates validity has been discussed in the literature. Practically speaking, a surrogate 
endpoint should have a positive statistical association with the gold-standard outcome, and changes in the 
surrogate endpoint over time should be associated with the outcome. Furthermore, there must be a 
plausible explanatory link between the surrogate endpoint and the outcome. In the current study, we 
examined evidence for the validity of chart-extracted exacerbations as a surrogate endpoint for mortality, 
as well as disease-related quality of life. We included several other measures as covariates in our 
empirical evaluation that may also have impact on mortality. These included those that might be 
confounding factors in examining the utility of chart-extracted exacerbations of heart failure (e.g., 
comorbid medical), as well as common demographic factors associated with exacerbations for other 
reasons (e.g., age, race/ethnicity). 
METHOD 
Subjects: Participants in this study were HF patients initially screened at the Philadelphia 
Veterans Affairs Medical Center (PVAMC) for the purpose of recruiting them for a pilot study of 
treatment adherence [7]. During the period of active recruitment for that study, patients who had an 
appointment in the Congestive Heart Failure (CHF) Clinic of the PVAMC, or had been recently referred 
to the CHF Clinic and been evaluated by echocardiogram were screened for potential recruitment into the 
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adherence study. The patients who fit criteria for this database study had a chart diagnosis of heart failure, 
and their medical record was examined further to confirm the diagnosis. Patients were required to meet 
the criteria of systolic dysfunction as indicated on an echocardiogram, with left ventricle ejection fraction 
(LVEF) ≤ 40%, or with well-documented diastolic dysfunction, right-side heart failure, or other heart 
disease documented as responsible for heart failure, and with a New York Heart Association (NYHA) 
Class I/II or above. We also entered an additional set of patients into the study that were well-
compensated (NYHA Class I) due to current management for HF and no current heart failure symptoms 
upon entry into the study (N=20). For entry into the study, these patients were required to have a well-
documented history of episodes of heart failure decompensation prior to the period examined in the 
current study (see below).  
Of 277 patients screened, 191 met criteria for inclusion. The patients were primarily older (M = 
64.4, SD = 11.7), male veterans (N = 2 females). Most of the patients were Black/African American 
(62.3%), 30.9% were White, and 1% reported Latino ethnicity; 5.8% were of unknown race or ethnicity. 
Only 33.5% of these patients had a marital partner, according to medical records. A minority of the 
patients had diastolic dysfunction only (N=18, 9.4%), and on average, patients had a high number of 
comorbid conditions, M = 4.4, SD = 2.3. For the patients with systolic dysfunction, the mean of each 
patients’ minimum LVEF was M = 26.2, SD = 11.0.  
A portion of these patients were approached and recruited for the pilot study regarding adherence 
to treatment (N = 40). There was a possibility that the patients participating in the adherence study would 
have different outcomes due to pre-existing differences in severity of illness from the larger cohort or 
because the assessment methods of the pilot study had a positive effect on the patient’s self-care. Thus, 
we examined differences in those patients in the pilot study compared to those that did not and found only 
minor differences. Using a series of two-sample t-tests, we found that participators had a lower mean age, 
M = 60.8, SD =11.2, compared to those that did not, M = 65.5, SD = 11.6, t = 2.7, p < .01, df = 189. 
There were no differences between the groups on the mean number of comorbid conditions, t = -1.42, p > 
.05, df = 50.7, minimum LVEF, t = 0.45, p > .05, df = 182, or number of adjusted clinical exacerbations 
per year, t = -0.40, p > .05, df = 189. In addition, a 2 X 2 chi-square test of participators vs. non-
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participators indicated that participators were not more likely to die within the follow-up period covered 
in the current study, χ2 = 0.69, p > .05, df = 1. A multivariate test of differences for these comparisons 
between the groups was not used because it would have eliminated too many patients from consideration 
due to patterns of missing data, resulting in an underpowered test. 
Definition of Chart-extracted Exacerbations of HF. The essential feature of coding chart-extracted 
exacerbations of HF (CEEs) was that the clinician judged that the patient was suffering from the 
decompensation of the underlying HF, along with supporting evidence in the clinical record to ensure that 
an exacerbation was being clearly designated. CEEs were defined as the presentation and documentation 
of at least two of the common following symptoms HF: new/worsened edema, increased weight, 
worsened dyspnea (at rest or on exertion), worsened orthopnea, worsened paroxysmal nocturnal dyspnea, 
jugular venous distention, and/or the decision by the physician to increase diuretic medication. If the 
symptoms present were not specific to HF when considering other conditions that the patients had (i.e., 
dyspnea attributed to chronic obstructive pulmonary disease), then that particular symptom was 
discounted. Exacerbations were also designated if the clinician explicitly noted in the electronic record 
that the patient was “volume overloaded” or “decompensated.” 
The total number of exacerbations was divided by the length of time in years that each patient’s 
electronic record was followed (see coding procedures), yielding an index of the number of adjusted 
exacerbations per year. An effort was made to define discrete exacerbations so that the index would not 
be artificially inflated. Patients who were evaluated in the emergency department or in an outpatient visit 
with their cardiologist and then subsequently hospitalized due to HF exacerbation were not counted for 
more than one exacerbation for this instance. Similarly, clinical symptoms across consecutive daily 
evaluations, such as in an inpatient hospitalization, were not counted more than once as an exacerbation.  
Coding Procedures: Our goal was to sample a sufficient period of time surrounding the entry of 
the patient into the clinical database to estimate CEEs and predict mortality risk on a prospective basis 
from that date of entry. The notes in subjects’ electronic records at the PVAMC were examined for 
clinical events such as outpatient visits with primary care or cardiology service appointments, 
hospitalizations, emergency department visits, and were coded for involving CEE of HF. Clinical events 
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were recorded for each patient beginning one year prior to the patient’s entry into the screening database 
for the pilot study [7] until either 1) the patient died, 2) six months past the termination of recruitment for 
the adherence pilot study, 3) until the patient was removed from consideration for the pilot study (i.e., due 
to dementia or another disqualifying condition). Patients were followed an average of 1.5 years, with a 
range of 1.0 – 2.3 (see Figure 1). Patients needed at least 1 year of data (entry into the database minus 1 
year) to be considered for the current study. CEEs were adjusted for most analyses, normalizing the index 
to the rate of CEEs per year. We also counted hospitalizations and created a similar index of 
hospitalizations per year for the analyses described below. 
Other clinical information was also coded from the patients’ electronic records, including the 
number of conditions noted in the following areas: 1) diabetes, 2) other endocrine disorders, 3) 
hypertension, 4) stroke, 5) circulatory disorders, 6) autoimmune or joint disease, 7) upper gastrointestinal 
diseases, 8) lower gastrointestinal diseases, 9) pulmonary disorders, 10) vision problems, 11) auditory 
problems, 12) skin diseases, 13) cancer, 14) liver diseases, 15) gall bladder disease, 16) kidney disease, 
17) broken bones, 18) anemia, 19) nutritional problems, 20) neurological disorders, 21) back or neck 
problems, 22) bleeding disorders. NYHA Class, as assigned by the patient’s cardiologist or nurse 
practitioner closest to the date of the patient’s entry into the tracking database, was recorded for each 
patient. Forty-five percent of the patients (N=88) did not have NYHA Class designations on the electronic 
record.  
Assessment of mortality. We examined the patients’ electronic records for evidence of mortality 
for the 2-year period following each patient’s date of entry into the screening database so that each patient 
would have a standard follow-up period regarding mortality. Approximately 1 year elapsed between the 
final closing date of the follow-up period and the final chart examination to determine if each patient died. 
This ensured that the report of death would appear in the veterans’ clinical records (if the patient had 
indeed died) when death occurred in care settings outside the Veterans Health Administration system.  
Additional measures. Patients who entered the adherence pilot study (N = 40) had available 
additional measures assessed by interview, and 27 patients were assessed at one or more additional 
interviews in which a 6-minute walk test was administered. [8] Measure relevant to the current study 
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include the Kansas City Cardiomyopathy Questionnaire [9] the Hamilton Depression Rating Scale [10], 
the Beck Hopelessness Scale [11], a 25-item version of the Hopkins symptoms Checklist [12, 13], and the 
6-minute walk test [8]. The mean of the available distances walked in the latter measure was used in the 
analyses presented below. These measures have demonstrated reliability and validity for use with this 
population. 
The procedures for screening the patients and including them in the current database study were 
reviewed and approved by the IRB of the Philadelphia VAMC. 
RESULTS 
Descriptive data regarding clinical exacerbations. Most of the patients  (72.2%) had at least 1 
chart extracted exacerbation (CEE) over the 1 – 2.3 year follow-up period. The distribution of the 
absolute number of CEEs in ascending order was as follows: 0 – 27.8%, 1 – 31.4%, 2 – 15.2%, 3 – 
11.0%, ≥ 4 – 14.6%. The mean and range of the CEEs per year, after adjusting for the length of each 
patient’s follow-up period, was M = 1.23 (SD = 1.41), range, 0 – 8.2.  
Reliability. In order to estimate the reliability of judgments regarding the occurrence of CEEs of 
HF, the judgments of two research assistants were examined on a subset of 15% of the patients (N = 30; a 
total of 270 visits or clinical events). For purposes of coding for the final data and the reliability analyses, 
the visits examined included outpatient visits to the patient’s cardiology provider, primary care provider, 
emergency department provider, or inpatient provider. The two raters were highly reliable in identifying 
CEEs (or identifying an event and deciding there was no exacerbation): Cohen’s kappa=.83. Errors in 
date identification of the clinical event (i.e., outpatient visit) had been reconciled prior to the analysis. 
Associations of exacerbations with clinical and demographic factors. The index of CEE of HF, 
adjusted for the length of follow-up period, was associated with factors reflecting poorer cardiac 
functioning (see Table 2). The CEE index was positively corrected with higher NYHA Class, and 
negatively correlated with functional status on the KCCQ and distance walked on the 6 MWT. As 
indicated in the table, the index of HF exacerbations was not associated with the number of comorbid 
medical conditions, age, or the left ventricle ejection fraction.  
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We also examined whether the number of exacerbations differed by White vs. non-White race as 
well as marital status, using t-tests of independent samples. CEE did not differ by race, t = -1.22, p > .05, 
df = 189, nor marital status, t = -0.30, p > .05, df = 180.  
In order to examine evidence that the CEE index reflected increasingly poorer functioning in an 
ordinal fashion, we examined the mean number of CEE adjusted for follow-up period, within each of the 
NYHA Classes. As can be see in Table 1, the mean CEEs increased in an ordinal fashion over the NYHA 
Classes represented by patients in the sample. The 95% confidence intervals suggest, however, that there 
is some overlap of the CEEs across the NYHA Classes. 
Prediction of mortality. A total of 30.4% (N = 58) of the patients died over the 2-year mortality 
follow-up period. We used logistic regression to examine whether CHF exacerbations predicted risk of 
mortality in this sample of patients, first testing a model with the following demographic and clinical 
variables as covariates: age, number of comorbid conditions, presence/absence of relationship partner, 
and White vs. non-White race. The results are presented in Table 3, and suggest that only the number of 
comorbid conditions was a significant covariate.  Including NYHA class and lowest LVEF limited the 
sample by almost half, and so we did not examine a model including those variables. The second model in 
the table examined CEEs as a predictor of mortality over the two years considering only the number of 
comorbid conditions as a covariate.  
An index of the number of adjusted hospitalizations per year were included in the final model in 
Table 3 in order to examine the utility of the CEE index after adjusting for this common surrogate 
endpoint. The results suggested that CEEs still conferred increased odds of 33% risk of mortality for each 
additional exacerbation per year, even when all-cause hospitalization rate was taken into account. Thus, 
the findings suggest that each additional HF exacerbation increased the odds of mortality over the span of 
the study. The magnitude of the association is noteworthy when compared to the effects of medical 
comorbidity. 
Survival odds associated with clinical exacerbations. We conducted a series of survival analyses 
in order to test the predictive value of CEE over the course of two years, using the Kaplan-Meier 
estimates of the survival function, with the time variable being the number of days from the entry of the 
Clinical exacerbations 
10 
 
patient into the study database and death. The data were right-censored by the end of the follow-up period 
for examining mortality (i.e., 730 days), for patients who remained alive at the end of the study.  
After examining the distribution of the exacerbation data, we tested two different cut-points 
strategies for defining the strata in the survival models in order to examine evidence for a criterion 
number of CEEs that confer risk of mortality over a 2-year follow up period. We first defined three strata 
using the number of CEEs adjusted for the length of the CEE follow-up period in the following way: CEE 
= 0, 0 < CEE ≤ 1, and CEE > 1. The number of comorbid medical conditions was entered as a covariate in 
each analysis because of the demonstrated importance of the variable in previous analyses. The test of 
heterogeneity of the strata was significant, indicating that the survival curves for the strata did differ, χ2 = 
9.53, p < .01, df = 2. The comorbidity covariate also was significant, χ2 = 3.95, p < .05, df = 1, indicating 
greater mortality risk associated with greater medical comorbidity. There was little separation between the 
survival curves for the groups with no exacerbations (77% survived) and those having an adjusted < CEE 
≤ 1 (76% survived), compared to those having more than 1 (54% survived).  
The second strategy defined two strata using a cut-point of 2 adjusted CEEs in the following way: 
0 ≤ CEE ≤ 2 and CEE > 2. The test of heterogeneity of the strata was significant, indicating that the 
survival curves for the strata were significantly different, χ2 = 8.47, p < .005, df = 1, and the comorbidity 
covariate was significant, χ2 = 4.09, p < .05, df = 1. As shown in Figure 1, patients with greater than 2 
adjusted CEEs survived at a lower rate, 46%, compared to those with 2 or fewer adjusted CEEs, of whom 
73% survived. The figure indicates that a good portion of mortality occurred within 100 days of the entry 
into the study, suggesting that patients with relatively higher numbers of clinical exacerbations were at 
greatest risk of dying in within the short-term (i.e. < ½ year).  
DISCUSSION AND CONCLUSIONS 
The central theme of the findings is that exacerbations of heart failure can be judged reliably from 
clinical notes by non-medical personnel and appear to be an early indicator of patients at risk of mortality. 
The index of HF exacerbations was associated with other indices of poor clinical functioning, NYHA 
class, HF related quality of life, and a measure of exercise capacity but was not associated with the 
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patients’ mean or lowest LVEF, age or the number of comorbid medical conditions. The index was a 
significant predictor of risk of mortality over 2-year period, even after adjusting for a variety of 
covariates. Preliminary evidence supports the role of this index as surrogate endpoint for mortality and 
disease-related quality of life. 
Importantly, our index of exacerbations was associated with increased risk of mortality even after 
adjusting for the patients’ number of hospitalizations per year and medical comorbidity. This suggests 
that exacerbations carry additional information about mortality risk over and above the overall severity of 
illness. Combined with the consistent associations with cardiac-related measures of functioning, the 
findings suggest that exacerbations represent mortality risk associated with poorer cardiac functioning and 
the progression of cardiac disease. This notion is consistent with evidence that patients with advanced 
heart failure develop nonresponsiveness to standard treatments such as furosemide. In a study by 
MacFadyen and colleagues,[14] the primary factor in patients’ poorer response to chronic furosemide 
treatment was intrarenal diuretic resistance, as opposed to non-adherence to the treatment. The authors 
suggested that increased resistance to diuretic medication and renal deterioration might serve as surrogate 
endpoints for the progression of the illness. 
Other factors than illness progression may result in clinical exacerbations, such as medication 
nonadherence, leading to the question of the appropriateness of the CEE index as a surrogate endpoint for 
mortality. Mortality, however, can also be adversely affected by poor treatment adherence. Similarly, 
poor education in self-care of HF can affect mortality risk, but clearly these factors affect mortality 
through influence on general illness progression and patients becoming volume-overloaded, which are 
central to the assessment of clinical exacerbations. Future research examining the escalation of clinical 
exacerbations in relation to the patient’s death may be particularly useful in understanding the predictive 
role of this index. As noted in the introduction, changes in surrogate endpoints should be proportionally 
associated with changes in a gold standard endpoint (i.e., death) and research is needed to document this 
with CEEs. 
This index of clinical exacerbations might be especially useful for signs of increased mortality risk for 
patients in clinical trials, particularly in cases when a patient is not hospitalized for a clinical 
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exacerbation. The current data suggest that it may be prudent to withdraw patients participating in a 
medication or care management randomized trial who decompensate repeatedly, when the experimental 
treatment represents an untested or higher risk approach to therapy. Another advantage to the index is that 
the cost of obtaining information on the occurrence of an exacerbation is minimal, especially when 
recorded prospectively. The advent of clinical tests for B-type natriuretic peptide (BNP) [15], may 
sharpen the identification and proper response to clinical exacerbations of HF. The basic strategy, 
however, of identification of clinical exacerbations appears to be a useful method of detecting patients 
who may be at relatively early risk of mortality.  
Our current strategy of following patients in an outpatient cardiology clinic in a VA medical center 
setting led to a number of limitations to the study. As noted above many patients may become 
nonresponsive to diuretic treatment and maintain a chronic fluid-overloaded state. This status is 
undoubtedly associated with increased mortality risk, but our method of counting exacerbations did not 
take into account patients who may have been in this chronic state. Also, our periods of follow-up varied 
by patient, leading to potential error in identification of exacerbations for patients with relatively shorter 
follow-up periods for detecting these episodes. Additionally, lack of our coders being blind to death status 
may have led to bias in recording CEEs. Coders could have been aware of patients who had died when 
they noted clinical exacerbations when surveying the electronic record. The assessment of clinical 
exacerbations was partly retrospective, in that we examined the 1-year period prior to the entry of the 
patient into the screening database. Furthermore, we may have missed some clinical exacerbations in 
creating the CEE index. A portion of the patients had additional providers outside the VA medical system, 
and exacerbations that occurred were not necessarily reported on in the patient’s electronic record in a 
reliable manner (i.e., hospitalizations that occurred in non-VA institutions). Finally, as noted above, a 
number of patients lacked information in the electronic record, such as NYHA Class or LVEF, which was 
necessary for building comprehensive predictive models of outcome. 
Future prospective research is needed to examine fully the potential utility of the index of chart-
extracted exacerbations of HF as a surrogate endpoint for mortality or disease-related quality of life. 
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Preliminary evidence, however, suggests that this index may serve well as a surrogate endpoint for both 
mortality and HF-related quality of life. 
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Table 1 Frequency of Patients in each New York Heart Association Class 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes:  NYHA = New York Heart Association. 
 95% CI = 95% confidence interval. 
N = 88 who were missing any designation of NYHA Class at the time of entry into the screening 
database. 
 
 
NYHA Class Frequency percent 
Mean Adjusted 
Exacerbations 
95% C.I. 
I 20 19.4 0.45 0.20 – 0.70 
I /II 9 8.7 0.67 0.09 – 1.25 
II 40 38.8 1.41 0.94 – 1.89 
II/III 13 12.6 1.49 0.69 – 2.29 
III 21 20.4 2.39 1.45 – 3.32 
III/IV – IV 0 0 – – 
Total 103 100.0 – – 
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Table 2 Correlations of Adjusted Exacerbations with Clinical and Demographic Variables 
 
 
Comorbidity 
Conditions  Age 
Minimum 
LVEF 
Mean 
LVEF NYHA KCCQ 
Mean 
6MWT 
distance 
Adjusted 
Exacerbations               
Per Year 
0.14 0.13 -.03 .02 0.41*** -.37* -.47** 
N 191 191 184 186 103 41 27 
 
Notes: * p < .05. ** p < .01. *** p < .001. 
NYHA  = New York Heart Association Class (I = 1, I/II = 2, II = 3, etc.) 
LVEF = Left Ventricle Ejection Fraction 
KCCQ = Kansas City Cardiomyopathy Questionnaire-Functional Status (higher scores = 
better functioning) 
6MWT distance = Distance walked in the 6 Minute Walk Test. 
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Table 3 Logistic Regression Models of Mortality 
 Variable OR 95% CI p 
Covariates only model  
N = 182,  
χ 2 = 13.97, p < .001 
Age 1.03 1.00 – 1.06 Ns 
 
Comorbid 
Conditions 
1.24 1.07 – 1.43 < .01 
 Partner 0.87 0.43 – 1.76 Ns 
 Race 1.47 0.73 – 2.97 Ns 
     
CEE model 
N = 191 
 
 
   
χ2 = 20.41, p < .0001 
Comorbid 
Conditions 
1.19 1.04 – 1.37 < .05 
 CEEs 1.48 1.17 – 1.87 < .005 
     
CEE and Hospitalization 
model 
N = 191 
χ2 = 28.87, p < .0001 
Comorbid 
Conditions 
1.15 0.99 – 1.33 ns 
 Hospitalizations 1.58 1.14 – 2.19 < .01 
 CEEs 1.33 1.02 – 1.72 < .05 
 
 
OR = odds ration. 95% CI  = 95% confidence interval. CEE = Chart Extracted Exacerbations.
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Figure 1 
 
Follow-up Period For Coding Exacerbations 
 
                                             Entry                                 Death/Termination 
                  into the Study                         of Recruitment 
                                                   ↓                                           ↓  
                  1 year             0 – 1.3 yrs 
│──────────────│─────────────────│ 
 
 
Follow-up Period for Death Determination    
                            End of Follow-up 
                                                                                                                                           ↓ 
                                                                          2 years  
                                      │──────────────────────────────────│  
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Survival Model for CEE Groups: <=2 Versus >2 Exacerbations Per Year 
Days to death 
 
